SARcode Biosciences, a biopharmaceutical company based in Brisbane, Calif., is being acquired by Shire, headquartered in Dublin, Ireland, for a $160 million upfront payment.
Shire intends to use the acquisition to expand its involvement in the therapeutic ophthalmology market.
Along with SARcode Biosciences, Shire will acquire the company's dry eye disease treatment, LIFITEGRAST.
Shire intends to launch LIFTEGRAST in the U.S. by 2016.
More Articles on Ophthalmology:
Austin Dell Laser Consultants Offers Laser Treatment Options
Johns Hopkins Offers Implantable Macular Degeneration Treatment
Hemera Biosciences Receives $3.8M for Development of Macular Degeneration Treatment
Shire intends to use the acquisition to expand its involvement in the therapeutic ophthalmology market.
Along with SARcode Biosciences, Shire will acquire the company's dry eye disease treatment, LIFITEGRAST.
Shire intends to launch LIFTEGRAST in the U.S. by 2016.
More Articles on Ophthalmology:
Austin Dell Laser Consultants Offers Laser Treatment Options
Johns Hopkins Offers Implantable Macular Degeneration Treatment
Hemera Biosciences Receives $3.8M for Development of Macular Degeneration Treatment